TuisABCL • NASDAQ
add
AbCellera Biologics Inc
Vorige sluiting
$3,64
Dagwisseling
$3,64 - $3,76
Jaarwisseling
$1,89 - $6,52
Markkapitalisasie
1,12 mjd USD
Gemiddelde volume
4,85 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 8,96 m | 37,62% |
Bedryfskoste | 30,20 m | -48,98% |
Netto inkomste | -57,12 m | -11,76% |
Netto winsgrens | -637,84 | 18,79% |
Wins per aandeel | -0,19 | -11,76% |
EBITDA | -71,03 m | -25,18% |
Effektiewe belastingkoers | 16,94% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 495,67 m | -22,93% |
Totale bates | 1,36 mjd | -2,64% |
Totale aanspreeklikheid | 391,95 m | 24,54% |
Totale ekwiteit | 964,04 m | — |
Uitstaande aandele | 299,34 m | — |
Prys om te bespreek | 1,12 | — |
Opbrengs op bates | -13,83% | — |
Opbrengs op kapitaal | -16,91% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -57,12 m | -11,76% |
Kontant van bedrywe | -52,59 m | -82,10% |
Kontant van beleggings | 36,49 m | 886,70% |
Kontant van finansiering | 7,37 m | 134,40% |
Netto kontantverandering | -9,28 m | 57,19% |
Beskikbare kontantvloei | -44,36 m | -323,45% |
Meer oor
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
HUB
Gestig
2012
Hoofkwartier
Webwerf
Werknemers
596
